Biofrontera Inc. (BFRI) intrinsic value & 10-year financials
Biofrontera Inc. (BFRI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 17.2% a year to $41.7M, with an average return on invested capital of -299.1%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.82
- Market cap
- $8.4M
- Revenue (FY2025)
- $41.7M
- Revenue growth (7-yr CAGR)
- 17.2%
- ROIC (10-yr avg)
- -299.1%
- Free cash flow (FY2025)
- -$13.4M
BFRI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $41.7M | -$10.5M | -$1.04 | -$13.4M | -27.2% | -549.3% |
| FY2024 | $37.3M | -$17.8M | -$3.22 | -$10.3M | -46.1% | -494.4% |
| FY2023 | $34.1M | -$20.1M | -$13.02 | -$24.9M | -66.6% | -289.3% |
| FY2022 | $28.7M | -$640.0K | -$0.61 | -$16.2M | -64.8% | -247.2% |
| FY2021 | $24.1M | -$37.7M | — | — | -104.6% | -293.6% |
| FY2020 | $18.8M | -$11.0M | — | — | -51.0% | 78.9% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Biofrontera Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Biofrontera Inc. has historically struggled to out-earn its cost of capital, averaging just -4.0% ROIC.
Biofrontera Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Biofrontera Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-34.54 per share.